Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 6
2012 3
2013 4
2014 4
2015 2
2016 3
2017 3
2018 6
2019 4
2020 6
2021 7
2022 5
2023 5
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Olsen IC, Lexberg ÅS, Madland TM, Fremstad H, Høili CA, Bakland G, Spada C, Haukeland H, Hansen IM, Moholt E, Uhlig T, Solomon DH, van der Heijde D, Kvien TK, Haavardsholm EA. Lillegraven S, et al. Ann Rheum Dis. 2023 Nov;82(11):1394-1403. doi: 10.1136/ard-2023-224476. Epub 2023 Aug 22. Ann Rheum Dis. 2023. PMID: 37607809 Free PMC article. Clinical Trial.
Reply.
Norvang V, Kvien TK, Uhlig T, Lillegraven S, Mjaavatten MD, Yoshida K, Solomon DH, Haavardsholm EA. Norvang V, et al. Among authors: lillegraven s. Arthritis Rheumatol. 2020 Aug;72(8):1407-1408. doi: 10.1002/art.41268. Epub 2020 Jun 10. Arthritis Rheumatol. 2020. PMID: 32249541 No abstract available.
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE, Sundlisæter NP, Aga AB, Sexton J, Olsen IC, Fremstad H, Spada C, Madland TM, Høili CA, Bakland G, Lexberg Å, Hansen IJW, Hansen IM, Haukeland H, Ljoså MA, Moholt E, Uhlig T, Kvien TK, Solomon DH, van der Heijde D, Haavardsholm EA, Lillegraven S. Kjørholt KE, et al. Among authors: lillegraven s. Lancet Rheumatol. 2024 May;6(5):e268-e278. doi: 10.1016/S2665-9913(24)00021-3. Epub 2024 Apr 4. Lancet Rheumatol. 2024. PMID: 38583450 Clinical Trial.
[Service user involvement can improve research].
Haavardsholm EA, Lillegraven S. Haavardsholm EA, et al. Among authors: lillegraven s. Tidsskr Nor Laegeforen. 2023 Jun 12;143(9). doi: 10.4045/tidsskr.23.0245. Print 2023 Jun 13. Tidsskr Nor Laegeforen. 2023. PMID: 37341398 Free article. Norwegian. No abstract available.
Rheumatology congresses post COVID-19: we cannot regress.
Nordberg LB, Vikse J, Heiberg MS, Lillejordet E, Mæhlen MT, Kristianslund EK, Provan SA, Lillegraven S. Nordberg LB, et al. Among authors: lillegraven s. Lancet Rheumatol. 2023 Jul;5(7):e370-e371. doi: 10.1016/S2665-9913(23)00153-4. Epub 2023 Jun 2. Lancet Rheumatol. 2023. PMID: 37360002 Free PMC article. No abstract available.
Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
Melokhina V, Paulshus Sundlisæter N, Sexton J, Sundin U, Aga AB, Kjørholt KE, Nordberg LB, van der Heijde D, Haavardsholm E, Lillegraven S. Melokhina V, et al. Among authors: lillegraven s. Ann Rheum Dis. 2024 Mar 12;83(4):540-541. doi: 10.1136/ard-2023-224950. Ann Rheum Dis. 2024. PMID: 38049997 No abstract available.
60 results